There is no separate peptide FDA approval process. A peptide—a short chain of amino acids—must clear the same basic path as another new drug: early safety work, permission to test in people, phased clinical trials, a full application, and review of both the evidence and the factory that will make it. Approval belongs to one product, for one labeled use. It does not bless every peptide or every version of that molecule.
As of September 6, 2026, the day this article was written, the newest clear example was Mimrylo (rusfertide). The agency approved it on August 28 for erythrocytosis, or too many red blood cells, in adults with polycythemia vera, a rare blood cancer. Takeda’s announcement—not a compounded product—reports the date and the trial behind the decision.
What Mimrylo’s approval actually shows
Mimrylo is a hepcidin mimetic, meaning it copies a natural hormone that controls where iron moves in the body. Less available iron can limit excess red-blood-cell production. Its current prescribing label describes an injection under the skin given weekly.
The decisive study was VERIFY, a phase 3 trial of 293 adults. Participants received Mimrylo or a placebo, a look-alike treatment without the active drug, alongside their usual care. From weeks 20 through 32, 76.9% of the Mimrylo group met the response definition, compared with 32.9% of the placebo group. Response meant keeping hematocrit—the share of blood made up of red cells—controlled without meeting the study’s threshold for phlebotomy, or therapeutic blood removal.
That phase 3 result did not appear from nowhere. An earlier 70-person phase 2 study called REVIVE established the clinical groundwork and was reported in the New England Journal of Medicine in 2024. This is what a development program looks like: each stage answers the next question, then the whole record is reviewed together.
The lesson is narrow but useful. One peptide completed the path for one disease and one formulation. It says nothing automatic about a peptide with a different sequence, purpose, or manufacturing process.
There is no shortcut in the peptide FDA approval process
The names make the route sound more mysterious than it is. Here is what each step is trying to settle.
| Step | Plain-English question | What happens |
|---|---|---|
| Before an IND | Is human testing reasonable? | Laboratory and animal work examines how the drug acts, early toxicology, and whether consistent batches can be made. |
| IND | Can the first human trial begin? | An investigational new drug application, or IND, gives the agency the study plan, safety evidence, and manufacturing information. FDA has 30 days to raise a clinical hold. |
| Phase 1 | What happens in people? | Usually 20 to 80 participants help researchers study safety, how the body handles the drug, and a workable dose range. |
| Phase 2 | Is there a useful signal? | A few dozen to about 300 people help refine dose, side effects, and whether the drug appears to help the intended condition. |
| Phase 3 | Does it hold up in a larger comparison? | Several hundred to about 3,000 participants provide the main evidence on benefits and risks for the proposed use. |
| NDA and review | Is the whole package good enough? | A new drug application, or NDA, combines trial results, ingredients, manufacturing, packaging, and the proposed label. Reviewers may approve it or send a complete response letter explaining what is missing. |
| After approval | What appears in wider use? | Safety monitoring continues, and the label can change as new evidence arrives. |
Those participant ranges come from FDA’s own step-by-step review guide. The agency does not ask whether a drug has zero risk. It asks whether the evidence shows its benefits outweigh its known risks for the proposed use, and whether the marketed product can be made consistently.
Peptides bring a few extra problems to solve
A peptide can be chemically delicate. Developers have to show that it stays intact and keeps the intended strength through manufacturing, shipping, and storage. They also have to identify impurities, because a slightly altered chain or leftover material from production may matter.
Then there is immunogenicity, the chance that the immune system reacts to the medicine. That can change safety or how well the drug works. A 2023 review of synthetic peptide drugs explains why both the peptide and manufacturing impurities are part of that risk assessment.
Route matters too. Digestive enzymes break many peptides apart, and the gut wall often absorbs them poorly. A 2021 drug-delivery review describes those two barriers plainly: enzyme breakdown and weak passage through the intestine. That is why many peptide medicines are injections.
A pill that works at the same receptor is not necessarily a peptide. As of September 6, 2026, the day this article was written, FDA’s 2026 novel-drug list recorded Foundayo (orforglipron) on April 1. It is an oral small molecule, not a peptide, even though it activates the GLP-1 receptor. Its tablet form does not prove that injectable peptides can simply be put into pills.
Approval does not transfer to a compounded version
The familiar names fall into two groups. Brand forms of semaglutide, tirzepatide, tesamorelin, bremelanotide (also called PT-141), and elamipretide (also called SS-31) have approvals for specific uses. That does not carry over to every formulation containing the same molecule.
The compounded formulations offered here are different from FDA-approved products: the formulations offered here are not FDA-approved. The dedicated pages explain why compounded semaglutide is not FDA-approved and compounded tirzepatide is not FDA-approved without turning this article into two brand histories.
BPC-157, TB-500, and MOTS-c have no U.S.-approved drug product. Compounding does not make them FDA-approved or place them at the end of an NDA review.
Compounding under section 503A is a different lane: a licensed pharmacist prepares a medication for an individual patient from a valid prescription when federal and state conditions are met. FDA explains that distinction in its compounding questions and answers. A licensed provider may still prescribe a compounded formulation when medically appropriate; that decision is between the patient and doctor.
At Promise, a licensed provider reviews every request, and not everyone qualifies.
What to watch after the decision
Approval is a checkpoint, not the end of evidence gathering. Wider use can reveal an uncommon side effect that a trial was too small to spot. A company may also run another trial and ask the agency to add a new use to the label.
For Mimrylo, the useful next pieces will be the full peer-reviewed VERIFY report and longer follow-up. They should make it easier to see how durable the response is and how the safety picture develops beyond the first comparison period.
Do not confuse that drug-review story with the separate debate over which bulk substances pharmacies may use in compounding. Our FDA peptide decision tracker follows that process. A committee vote on a compounding list is not an NDA, a phase 3 result, or a product approval.